ReviewDrugs & aging2019
Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.
Review in Drugs & aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Effect of acupuncture on monoaminergic neurotransmitters in animal models of vascular dementia: a preclinical systematic review and meta-analysis.Frontiers in physiology · 2026Pooled it
- Efficacy of 5 and 10 mg donepezil in improving cognitive function in patients with dementia: a systematic review and meta-analysis.Frontiers in neuroscience · 2024Pooled it
- Eight-week multi-domain cognitive training does not impact large-scale resting-state brain networks in Parkinson's disease.NeuroImage. Clinical · 2022Trial
- Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.Journal of Alzheimer's disease : JAD · 2020Trial
- Observational
- Use of Amyloid Positron-Emission Tomography to Diagnose Alzheimer's Disease in Clinical Practice in South Korea: Expert Recommendations.Journal of clinical neurology (Seoul, Korea) · 2025Review
- Acetylcholine deficit causes dysfunctional inhibitory control in an aging-dependent manner.Scientific reports · 2022Article
- Nutritional and Phyto-Therapeutic Value of the HalophytePlants (Basel, Switzerland) · 2022Article
- Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy.Orphanet journal of rare diseases · 2022Review
- The Antiviral Drug Tilorone Is a Potent and Selective Inhibitor of Acetylcholinesterase.Chemical research in toxicology · 2021Article
- Pharmacotherapy for Frontotemporal Dementia.CNS drugs · 2021Review
- The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer's Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study.Clinical interventions in aging · 2021Article
- Fluid Biomarkers of Frontotemporal Lobar Degeneration.Advances in experimental medicine and biology · 2021Article
- Molecular Factors Mediating Neural Cell Plasticity Changes in Dementia Brain Diseases.Neural plasticity · 2021Review
- Neuromodulation of Persistent Activity and Working Memory Circuitry in Primate Prefrontal Cortex by Muscarinic Receptors.Frontiers in neural circuits · 2021Review
- Donepezil-related inadequate neuromuscular blockade during laparoscopic surgery: A case report.World journal of clinical cases · 2020Article
- Basal forebrain atrophy in frontotemporal dementia.NeuroImage. Clinical · 2020Article
- Clinical drug development for dementia with Lewy bodies: past and present.Expert opinion on investigational drugs · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-Alzheimer's dementias constitute 30% of all dementias and present with major cognitive and behavioral disturbances. Cholinesterase inhibitors improve memory by increasing brain acetylcholine levels and are approved symptomatic therapies for Alzheimer's disease (AD). They have also been investigated in other types of dementias with potential cholinergic dysfunction. There is compelling evidence for a profound cholinergic deficit in Lewy Body dementia (LBD) and Parkinson's disease dementia (PDD), even to a greater extent than AD. However, this deficit is difficult to objectivize in vascular dementia (VaD) given the increased comorbidity with AD. Furthermore, there is minimal to no evidence for cholinergic loss in frontotemporal dementia (FTD). Although cholinesterase inhibitors showed significant improvement in cognitive, behavioral, and functional measures in both LBD and PDD clinical trials, only rivastigmine is approved for PDD, due to the heterogeneity of the scales used, the duration of trials, and the limited sample sizes impacting data interpretation. Similarly, the interpretation of findings in VaD trials are limited by the lack of pre-defined inclusion criteria for 'pure VaD' and the wide heterogeneity of patients enrolled with respect to location and extent of cerebrovascular disease. In FTD patients, cholinesterase inhibitors were mostly associated with worsening of cognitive and behavioral symptoms. In non-AD dementias, cholinesterase inhibitors were well tolerated, with increased reports of mild to moderate cholinergic side effects and a non-significant trend for increased cardio and cerebrovascular events with rivastigmine in VaD, justifying their cautious use on a case-by-case basis, especially when there is evidence for cholinergic deficit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.